Condition: Gastric Cancer (GC) · Gastroesophageal Junction Adenocarcinoma · Sponsor: Jingdong Zhang
To investigate the efficacy of SHR-1701 combined with Rivoceranib, with or without SHR-2554, in patients with gastric or gastroesophageal junction adenocarcinoma who have progressed on or were intolerant to first-line immunotherapy-containing treatment
This description comes directly from the study's public registry record.
Qian Dong, Doctor · 17309815028 · dongqian08@163.com
Always discuss trial participation with your own doctor first.
| Liaoning Provincial Cancer Hospital | Shenyang, Liaoning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07311408